Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Financing Activities (2023 - 2025)

Historic Cash from Financing Activities for Corvus Pharmaceuticals (CRVS) over the last 3 years, with Q3 2025 value amounting to $360000.0.

  • Corvus Pharmaceuticals' Cash from Financing Activities rose 62000.0% to $360000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $55.0 million, marking a year-over-year increase of 59632.96%. This contributed to the annual value of $49.0 million for FY2024, which is 52416.3% up from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Cash from Financing Activities stood at $360000.0, which was up 62000.0% from $35.8 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Cash from Financing Activities peaked at $35.8 million during Q2 2025, and registered a low of $4000.0 during Q1 2023.
  • Over the past 3 years, Corvus Pharmaceuticals' median Cash from Financing Activities value was $347500.0 (recorded in 2023), while the average stood at $7.9 million.
  • As far as peak fluctuations go, Corvus Pharmaceuticals' Cash from Financing Activities plummeted by 8507.46% in 2024, and later surged by 62000.0% in 2025.
  • Corvus Pharmaceuticals' Cash from Financing Activities (Quarter) stood at $335000.0 in 2023, then surged by 5454.63% to $18.6 million in 2024, then tumbled by 98.07% to $360000.0 in 2025.
  • Its Cash from Financing Activities was $360000.0 in Q3 2025, compared to $35.8 million in Q2 2025 and $279000.0 in Q1 2025.